38results about "Cytokine-induced proteins" patented technology

PCT No. PCT/US96/08992 Sec. 371 Date Jun. 5, 1996 Sec. 102(e) Date Jun. 5, 1996 PCT Filed Jun. 5, 1996Disclosed are an isolated antibody or antibody fragment that selectively binds a polypeptide encoded by Cytokine Response gene 2 (CR2), and in particular, selectively binds to a first polypeptide having the sequence of residues 1-60 of SEQ. ID No: 4. Also disclosed is a composition containing the antibody or antibody fragment and a diluent or carrier. Also disclosed are methods, using the present antibody or antibody fragment, of isolating or purifying a peptide comprising an amino acid sequence of residues 1-60 of SEQ. ID No: 4 or an antibody binding fragment thereof that is at least 10 to 30 amino acids long, or a fusion protein comprising any of these.

Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

The present invention provides a fusion protein in which a polypeptide comprising Fas-1 domain is fused in frame to N-terminal or C-terminal of human EGF, a nucleotide sequence encoding the fusion protein, an expression vector containing the nucleotide sequence, a transformant transformed by the nucleotide sequence and a method for producing human EGF, improving stability of the protein and enhancing the functions of the same. The present invention provides human EGF with improved stability and enhanced functions by fusing a polypeptide comprising Fas-1 domain having the activities of cell adhesion and wound healing to human EGF.

Dickkopf (Dkk) proteins inhibit the canonical Wnt signaling pathway. Each of the members of the Dkk family has been previously cloned and expressed as a soluble protein in eukaryotic cells, while expression in bacterial cells has resulted in the formation of insoluble inclusion bodies that require further processing. The present invention provides compositions and methods for producing soluble, active dkk protein in prokaryotic host cells, by expressing the dkk protein as a fusion protein with a solubilization molecule, thereby providing an inexpensive and convenient source of pure active Dkk.

The invention relates to purified proteins induced in human cells by interferon alpha or beta, RNAs, DNAs and hybrid vectors coding for said proteins, hosts transformed with such a hybrid vector, processes for the preparation and purification of these proteins, DNAs, vectors and hosts, monoclonal antibodies specific to these proteins, monoclonal antibody derivatives, hybridoma cell lines secreting these monoclonal antibodies, the use of the monoclonal antibodies and their derivatives in the qualitative and quantitative determination of these proteins, test kits containing the monoclonal antibodies, and pharmaceutical preparations containing said proteins. A protein of the invention shows antiviral properties ascribed to interferons and may be a valuable indicator of the cell response to an interferon therapy.

(Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFRα-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body.

(Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFRα-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFRα-positive cells.

The present invention relates to a recombinant receptor, comprising a ligand-binding domain and a signaling domain that comprises a heterologous bait polypeptide, which receptor is inactivated by binding of a prey polypeptide to the heterologous bait peptide, either in presence or absence of a ligand binding to the ligand-binding domain. The receptor is activated by addition of a compound that disrupts the bait-prey interaction. The present invention also relates to a method of screening compounds that disrupt compound-compound-binding using the recombinant receptor.

The subject invention concerns peptide mimetics of SOCS proteins and methods of use. In one embodiment, a peptide mimetic of the invention binds to a SOCS1 and a SOCS3 target protein. In a specific embodiment, a peptide mimetic of the invention comprises the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:51, or a functional fragment or variant thereof. In a further embodiment, a peptide of the invention can comprise multiple copies of the mimetic sequence. In one embodiment, a peptide of the invention comprises two or more copies of SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:51. In a specific embodiment, a peptide mimetic of the invention comprises the amino acid sequence of SEQ ID NO:3 and/or SEQ ID NO:4 to and/or SEQ ID NO:52, or a functional fragment or variant thereof. The subject invention also pertains to methods of treating and/or preventing autoimmune conditions and/or disorders. In one embodiment, one or more peptide mimetics of the invention are used to treat an autoimmune condition or disorder in a person or animal. In a specific embodiment, a mimetic of the invention is used to treat SLE in a person or animal. The subject invention also concerns methods for diagnosing and/or monitoring progression of SLE in a person or animal.

A method can be used for treating or reducing likelihood of an influenza A virus-induced disease in a mammal. The method includes administering a polynucleotide to the mammal. Theis polynucleotide includes a gene encoding Mx protein having a TRAF2 and/or a TRAF6 binding domain. The TRAF2 and/or TRAF6 binding domain can be represented by the sequences P-X-Q/E-E, P-X-Q/E-X-X-D, or P-X-E-E-X-E. The TRAF2 and/or TRAF6 binding domain can also be located in the Mx protein in a position which corresponds to the position of the hexapeptide PEEESE in the bovine Mx1 protein or in a position which is up to 20 amino acid residues upstream or downstream of that position.

Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating Kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an IL-10 agent are also provided.

The present invention relates to identification of a gene upregulated by interferon-administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon- and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.

The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitreous delineating agents that comprise a hyaluronan binding peptide linked to an optically detectable moiety. Such compositions can be in a formulation that may be a solution, a suspension, or an emulsion, and would be injected into the vitreous shortly prior to use. The composition may additionally contain a therapeutic agent, a diagnostic agent, or a chemosensing material, in use, the composition marks or delineates the vitreous by binding preferentially to the hyaluronan that permeates the vitreous humor and binding little or not at all to surrounding tissues such as the retina. The interface between the labelled vitreous humor and the non-labelled surrounding vital tissues produces a visible signal, thereby allowing a surgeon to clearly visualize the entire vitreous cavity and distinguish it from vital ocular structures. Use of the method improves the accuracy and safety of a vitrectomy and thus prevents suboptimal outcomes or the need for repeated procedures. The compositions comprising chemosensing material are useful as long-lasting biosensors, which when used in the vitreous enable repetitive, non-invasive, in vivo measurements of metabolites or pharmacologic agents in the vitreous of animals or humans.

Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.